bullish
Green Cross (006280 KS): Hope Still Remains for the U.S. Approval of Blood Derivative Injection
374 Views23 Jun 2022 16:45
SUMMARY
- Green Cross (006280 KS) is expected to receive FDA approval for its immune globulin injection, once the agency conducts onsite inspection of its production facility.
- After suffering in 2021, both blood products and vaccine business are back to double-digit growth path in Q1 2022. The company continues to win export orders for both of these.
- Hunter syndrome and hemophilia treatments are the company’s new growth engines. Green Cross has received approval for its hunter syndrome treatment in China and Japan.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Rising
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Green Cross (006280 KS): Alyglo Is Accelerating U.S. Market Entry; Base Business Shows Strength24 Sep 2024
- Green Cross (006280 KS): Turns Profitable in Q2; All Eyes on the Maiden US Approval of Blood Product16 Aug 2023
- Green Cross (006280 KS): Strengthening Base Business; US Entry Remains Key Catalyst19 Oct 2022
- Green Cross (006280 KS): Look Ahead for Key Milestones Amid Covid Vaccine Related Setback15 Jan 2022
x